• Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)

  NCT00863148

  CompletedInterventionalPhase 2Updated Jul 19, 2017
• Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure

  NCT01188174

  CompletedInterventionalPhase 2Updated Dec 5, 2014
• Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission

  NCT07644481

  Not yet recruitingInterventionalNot ApplicableUpdated Jun 12, 2026
• Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML

  NCT04002115

  TerminatedInterventionalPhase 2Updated Sep 14, 2023
• Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen

  NCT00852163

  CompletedInterventionalPhase 2Updated Apr 4, 2013
• Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)

  NCT01422603

  CompletedInterventionalPhase 1Phase 2Updated Sep 7, 2018

ClinicalTrials.gov ID

NCT05917405

Lead Sponsor

Nantes University HospitalOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

302Estimated

Last Update Posted

Jan 30, 2026Actual

Start Date

Sep 14, 2023Actual

Primary Completion Date

Sep 14, 2028Estimated

Completion Date

Sep 14, 2028Estimated

Official Title

FLUCLORIC: Randomized Multicentric Phase III Study Comparing the Efficacy of 2 Reduced Intensity Conditioning Regimens (Clofarabine/Busulfan vs Fludarabine/Busulfan) in Adults With AML and Eligible to Allogeneic Stem Cell Transplantation

Brief Summary

Relapse remains the main cause of death in patients with myeloid malignancies, especially after an allotransplant. Using drugs with higher anti-leukemic activity as part of the conditioning regimen is one of the strategies to decrease relapse incidence in this population. Retrospective studies have shown that clofarabine can achieve impressive results compared to the use of fludarabine in acute myeloid leukemia (AML) as part of the conditioning regimen. Confirming such results in a prospective manner would definitely establish the CloB2A2 as a superior reduced-intensity conditioning (RIC) regimen compared to the FB2A2 for AML patients.302 AML patients (151 in each arm) in complete remission at transplant will be included with the main objective to demonstrate a significant better 2-year overall survival for CloB2A2 cases (70% vs 55%). A cost-utility analysis and a cost-effectiveness analysis will be also performed as well as an assessment of the quality of life after transplant. Clofarabine will be furnished to all centers. The duration of the study will be 5 years with 3 years of inclusion and 2 years of follow-up for each patient.

• Acute Myeloid Leukemia in Remission

• Fludarabine
• Busulfan
• ATG
• Clofarabine

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

Age ≥ 18 years' old

• De novo or secondary AML (according to ELN 2022 classification) in complete cytological remission at time of transplant (bone marrow blast count < 5%) or MDS/LAM with bone marrow blast count ≤ 5%

• Patients in first or second line therapy are allowed

• Patient eligible to a RIC regimen : patients aged ≥ 60 year old or <60 with co-morbidity(ies).

• Patient with a related or an unrelated matched donor

• Graft using only peripheral blood stem cells

• Performance status ECOG 0 - 2

• Who provide their written informed consent

• Previous allograft allowed

• Affiliated with French social security system or beneficiary from such system

• Women must meet one of the following criteria at the time of inclusion:

  • use adequate contraceptive measures as recommended by the CTFG (Recommendations related to contraception and pregnancy testing in clinical trials v1.1; includes injectable implants, dual hormone birth control pills, intrauterine devices, abstinence from sex, or a sterilized partner), and have a negative pregnancy test (urine or serum pregnancy test) prior to receiving the first dose of study drug;
  • or be post-menopausal (over 50 years of age with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal therapy)
  • or (if under 50 years of age) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal therapy and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels corresponding to post-menopausal levels
  • or have undergone irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (this operation must be documented).
  • Contraception methods must be prescribed using effective contraceptive methods during treatment and within 6 months for women of childbearing age (WOCB) and 6 months for men in case they have sexual relations with WOCB after the last dose of Fludarabine/Clofarabine.

Exclusion Criteria:

• Pro-myelocytic leukemia
• Patient eligible to a myeloablative conditioning regimen
• Patient with haploidentical, mismatched unrelated donor or umbilical cord blood
• Pregnant or breastfeeding woman or patient refusing contraceptive mesures
• HIV positive
• Active Hepatitis B or C
• Left ventricular ejection fraction < 50%.
• DLCOc <40%
• Uncontrolled infection
• Uncontrolled haemolytic anaemia
• Creatinine clearance < 50 ml/min (evaluated by MDRD or CKDEPI).
• Serum bilirubine > 30 mmol/l, Cytolysis > 5 the upper limit range
• Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 2 years
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
• Participation to another interventional study during the last month or expected participation to another interventional study during participation to the FLUCLORIC study.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Nantes University HospitalOTHER

joris.magalie@chu-amiens.fr032245466

Syfrancois@chu.angers.fr0241354472

aberceanu@chu-besancon.fr0381668232

Gaelle.guillerm@chu-brest.fr0298223395

chantepie-s@chu-caen.fr0231272073

florence.beckerich@aphp.fr0149812053

MCarre@chu-grenoble.fr0476769445

Pascal.turlure@chu-limoges.fr0555056642

helene.labussiere-wallet@chu-lyon.fr0472117402

M.RUBIO@chru-nancy.fr0383153030

Mohamad.mohty@inserm.fr0149282620

jeanbaptiste.mear@chu-rennes.fr0299284291